Switch theme
Sign up to access all valuation multiples
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
2020
570
LTM Revenue $232M
LTM EBITDA $10.3M
$410M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Maravai LifeSciences has a last 12-month revenue (LTM) of $232M and a last 12-month EBITDA of $10.3M.
In the most recent fiscal year, Maravai LifeSciences achieved revenue of $259M and an EBITDA of -$157M.
Maravai LifeSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Maravai LifeSciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $232M | XXX | $259M | XXX | XXX | XXX |
| Gross Profit | $89.1M | XXX | $108M | XXX | XXX | XXX |
| Gross Margin | 38% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $10.3M | XXX | -$157M | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | -61% | XXX | XXX | XXX |
| EBIT | -$38.2M | XXX | -$72.7M | XXX | XXX | XXX |
| EBIT Margin | -16% | XXX | -28% | XXX | XXX | XXX |
| Net Profit | -$44.5M | XXX | -$145M | XXX | XXX | XXX |
| Net Margin | -19% | XXX | -56% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Maravai LifeSciences's stock price is $2.
Maravai LifeSciences has current market cap of $324M, and EV of $410M.
See Maravai LifeSciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $410M | $324M | XXX | XXX | XXX | XXX | $-0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Maravai LifeSciences has market cap of $324M and EV of $410M.
Maravai LifeSciences's trades at 1.6x EV/Revenue multiple, and -2.6x EV/EBITDA.
Equity research analysts estimate Maravai LifeSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Maravai LifeSciences has a P/E ratio of -7.3x.
See valuation multiples for Maravai LifeSciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $324M | XXX | $324M | XXX | XXX | XXX |
| EV (current) | $410M | XXX | $410M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 39.8x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBIT | -10.7x | XXX | -5.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.3x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | -15.3x | XXX | -17.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMaravai LifeSciences's last 12 month revenue growth is -13%
Maravai LifeSciences's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Maravai LifeSciences's rule of 40 is 234% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Maravai LifeSciences's rule of X is -27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Maravai LifeSciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -13% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | -61% | XXX | XXX | XXX |
| EBITDA Growth | -281% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 234% | XXX | -73% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -27% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 70% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Maravai LifeSciences acquired XXX companies to date.
Last acquisition by Maravai LifeSciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Maravai LifeSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Maravai LifeSciences founded? | Maravai LifeSciences was founded in 2020. |
| Where is Maravai LifeSciences headquartered? | Maravai LifeSciences is headquartered in United States of America. |
| How many employees does Maravai LifeSciences have? | As of today, Maravai LifeSciences has 570 employees. |
| Who is the CEO of Maravai LifeSciences? | Maravai LifeSciences's CEO is Mr. William E. Martin, III. |
| Is Maravai LifeSciences publicy listed? | Yes, Maravai LifeSciences is a public company listed on NAS. |
| What is the stock symbol of Maravai LifeSciences? | Maravai LifeSciences trades under MRVI ticker. |
| When did Maravai LifeSciences go public? | Maravai LifeSciences went public in 2020. |
| Who are competitors of Maravai LifeSciences? | Similar companies to Maravai LifeSciences include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Maravai LifeSciences? | Maravai LifeSciences's current market cap is $324M |
| What is the current revenue of Maravai LifeSciences? | Maravai LifeSciences's last 12 months revenue is $232M. |
| What is the current revenue growth of Maravai LifeSciences? | Maravai LifeSciences revenue growth (NTM/LTM) is -13%. |
| What is the current EV/Revenue multiple of Maravai LifeSciences? | Current revenue multiple of Maravai LifeSciences is 1.8x. |
| Is Maravai LifeSciences profitable? | Yes, Maravai LifeSciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Maravai LifeSciences? | Maravai LifeSciences's last 12 months EBITDA is $10.3M. |
| What is Maravai LifeSciences's EBITDA margin? | Maravai LifeSciences's last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Maravai LifeSciences? | Current EBITDA multiple of Maravai LifeSciences is 39.8x. |
| What is the current FCF of Maravai LifeSciences? | Maravai LifeSciences's last 12 months FCF is -$26.8M. |
| What is Maravai LifeSciences's FCF margin? | Maravai LifeSciences's last 12 months FCF margin is -12%. |
| What is the current EV/FCF multiple of Maravai LifeSciences? | Current FCF multiple of Maravai LifeSciences is -15.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
